Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002
暂无分享,去创建一个
N. Girard | T. Schuster | M. Olivier | H. Blanché | J. Trédaniel | G. Zalcman | S. Villar | P. Souquet | J. McKay | R. Gervais | F. Vaca-Paniagua | M. Vallée | F. Le Calvez-Kelm | P. Foucher | L. Guilleminault | S. Couraud | F. Morin | P. Missy | M. Vincent | J. Oliver | J. Margery | N. Prim | S. Larivé | B. Duvert | J. Mckay | Felipe Vaca-Paniagua | Laurent Guilleminault
[1] C. Paweletz,et al. Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA , 2014, Clinical Cancer Research.
[2] R. McCormack,et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study , 2013, British Journal of Cancer.
[3] Jaafar Bennouna,et al. Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients. , 2013, Lung cancer.
[4] Philip Quirke,et al. Accurately Identifying Low‐Allelic Fraction Variants in Single Samples with Next‐Generation Sequencing: Applications in Tumor Subclone Resolution , 2013, Human mutation.
[5] H. Blanché,et al. [Lung cancer in never smokers: a French national cohort (BioCAST/IFCT-1002)]. , 2013, Revue des maladies respiratoires.
[6] K. Nishio,et al. Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor , 2013, Cancer science.
[7] B. Milleron,et al. [Lung cancer in never smokers: a French national cohort (BioCAST/IFCT-1002)]. , 2013, Revue des maladies respiratoires.
[8] Jae Cheol Lee,et al. Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping , 2013, Journal of experimental & clinical cancer research : CR.
[9] D. Planchard,et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] T. Mok,et al. Detection of EGFR-activating mutations from plasma DNA as a potent predictor of survival outcomes in FASTACT 2: A randomized phase III study on intercalated combination of erlotinib (E) and chemotherapy (C). , 2013 .
[11] N. Rosenfeld,et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.
[12] Philip Hugenholtz,et al. Shining a Light on Dark Sequencing: Characterising Errors in Ion Torrent PGM Data , 2013, PLoS Comput. Biol..
[13] Vincent Ferretti,et al. Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial , 2013, International journal of cancer.
[14] Carlos Caldas,et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.
[15] A. Jakobsen,et al. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. , 2013, Lung cancer.
[16] L. Pusztai,et al. Cancer heterogeneity: implications for targeted therapeutics , 2013, British Journal of Cancer.
[17] Bruce E Johnson,et al. The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[18] G. Parmigiani,et al. Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing , 2012, Science Translational Medicine.
[19] U. Banerji,et al. Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers , 2012, PloS one.
[20] Torunn I Yock,et al. Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. , 2012, Cancer research.
[21] J. Soria,et al. Tumour molecular profiling for deciding therapy—the French initiative , 2012, Nature Reviews Clinical Oncology.
[22] Jun Wang,et al. Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I–IV Non-Small Cell Lung Cancer Patients , 2012, Respiration.
[23] J. Chung-Man Ho,et al. EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[24] B. Faircloth,et al. Primer3—new capabilities and interfaces , 2012, Nucleic acids research.
[25] Sébastien Couraud,et al. Lung cancer in never smokers--a review. , 2012, European journal of cancer.
[26] J. Shih,et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. , 2012, The Lancet. Oncology.
[27] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..
[28] L. Bubendorf,et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. , 2012, Lung cancer.
[29] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[30] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[31] Koichi Goto,et al. Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[32] Kikuya Kato,et al. Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas , 2011, Clinical Cancer Research.
[33] S. Kimura,et al. A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[34] K. Matsuo,et al. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Jun Ma,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.
[36] Hyae-Young Kim,et al. Circulating Cell-Free DNA in Plasma of Never Smokers with Advanced Lung Adenocarcinoma Receiving Gefitinib or Standard Chemotherapy as First-Line Therapy , 2011, Clinical Cancer Research.
[37] Klaus Pantel,et al. Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.
[38] H. Hakonarson,et al. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.
[39] V. Rusch,et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[40] Caicun Zhou,et al. Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer , 2010, Journal of Cancer Research and Clinical Oncology.
[41] X. Wang,et al. Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non–Small Cell Lung Cancer , 2010, Clinical Cancer Research.
[42] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[43] P. Jänne,et al. Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer , 2009, Clinical Cancer Research.
[44] Mehmet Toner,et al. Detection of mutations in EGFR in circulating lung-cancer cells. , 2008, The New England journal of medicine.
[45] K. Nishio,et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA) , 2007, British Journal of Cancer.
[46] R. Rosell,et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. , 2003, Cancer letters.
[47] D. Saville. Multiple Comparison Procedures: The Practical Solution , 1990 .
[48] J. Pignon,et al. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms. , 2014, The Journal of molecular diagnostics : JMD.
[49] Peiyong Jiang,et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. , 2013, Clinical chemistry.
[50] Lin Huan,et al. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .
[51] S. Goodman,et al. Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.